FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Meeting

May 27, 2021

QUESTIONS

---

1. **DISCUSSION:** The Applicant is seeking approval of teplizumab to delay clinical type 1 diabetes mellitus (T1D) in at-risk individuals. Discuss the strength of the overall evidence presented herein to conclude that effectiveness has been established for teplizumab for the proposed indication.

2. **DISCUSSION:** Discuss the clinical meaningfulness of the observed median 2-year delay of onset of T1D demonstrated in study TN-10.

3. **DISCUSSION:** Discuss your view of the safety issues identified in the clinical development program and the potential for unobserved, longer latency safety issues (e.g., malignancy) given the mechanism of action of teplizumab. Discuss whether these safety concerns can be adequately mitigated through labeling and/or required postmarketing studies.

4. **DISCUSSION:** The Applicant's proposed indication statement is "Teplizumab is for the delay of clinical type 1 diabetes mellitus (T1D) in at-risk individuals." TN-10 was conducted in individuals ages 8 and older and enrolled relatives of patients with T1D with two or more positive autoantibodies and dysglycemia. Based on available data, discuss how the indicated population should be described to ensure that the expected benefit(s) of teplizumab will outweigh the risks of treatment. If you have any other recommendations for the indication statement, please provide them.

5. **VOTE:** Does the information provided in the background documents and presentations by the Applicant and FDA show that the benefits of teplizumab outweigh the risks in support of approval to delay clinical type 1 diabetes mellitus?

    a. If you voted yes, provide your opinion on the appropriate indication statement and discuss whether you recommend any post-marketing safety studies.

    b. If you voted no, provide your rationale and provide recommendations for additional data and/or analyses that would support a favorable benefit-risk profile and approval of teplizumab.